Noxxon Pharma Ag

Bernd Eschgfäller

Sven Klussmann

Klaus Schiene

Gregor Bahrenberg

Christian Maasch

Florian Jarosch

Axel Vater

Steffen Helmling

Christian Lange

Clemens Gillen

Mathias Bell

Elisabeth Moyroud

Sandra Stark

Thorsten Ruppert

The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.

CGRP binding nucleic acids

The present invention relates to a modified L-nucleic acid, comprising a L-nucleic acid part and a non-L-nucleic acid part, whereby the L-nucleic acid part is conjugated to the non-L-nucleic acid part and the conjugation of the L-nucleic acid part with the non-L-nucleic acid past leads to a slowed elimination out of the organism, in comparison with a L-nucleic acid which only comprises the L-nucleic acid part, said L-nucleic acid part being a spiegelmer.

Modified L-nucleic acid

Growing community of inventors

Basel, Switzerland

Bernd Eschgfäller